Sonelokimab: PsA Relief with IL-17 Nanobody – Phase 2 Trial
New Nanobody Therapy Shows Promise for Psoriatic Arthritis Patients Groundbreaking results from a phase 2 clinical trial offer renewed hope for individuals battling psoriatic arthritis. The ARGO trial demonstrated that a novel nanobody, designed to target both IL-17A and IL-17F, significantly improved disease response rates compared to a placebo in patients with active forms of … Read more